BR112022022599A2 - Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma - Google Patents

Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma

Info

Publication number
BR112022022599A2
BR112022022599A2 BR112022022599A BR112022022599A BR112022022599A2 BR 112022022599 A2 BR112022022599 A2 BR 112022022599A2 BR 112022022599 A BR112022022599 A BR 112022022599A BR 112022022599 A BR112022022599 A BR 112022022599A BR 112022022599 A2 BR112022022599 A2 BR 112022022599A2
Authority
BR
Brazil
Prior art keywords
methods
covid
analogs
treatment
bardoxolone methyl
Prior art date
Application number
BR112022022599A
Other languages
English (en)
Portuguese (pt)
Inventor
Ferguson Deborah
Christian Wigley W
Meyer Colin
Warren Huff J
M Kral Robert Jr
Original Assignee
Reata Pharmaceuticals Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Holdings Llc filed Critical Reata Pharmaceuticals Holdings Llc
Publication of BR112022022599A2 publication Critical patent/BR112022022599A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022022599A 2020-05-09 2021-05-07 Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma BR112022022599A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022479P 2020-05-09 2020-05-09
US202063053056P 2020-07-17 2020-07-17
PCT/US2021/031282 WO2021231208A1 (en) 2020-05-09 2021-05-07 Methods of treating covid-19 using bardoxolone methyl or analogs thereof

Publications (1)

Publication Number Publication Date
BR112022022599A2 true BR112022022599A2 (pt) 2023-03-21

Family

ID=76197607

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022599A BR112022022599A2 (pt) 2020-05-09 2021-05-07 Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma

Country Status (10)

Country Link
US (1) US20230255982A1 (https=)
EP (1) EP4146226A1 (https=)
JP (1) JP2023526567A (https=)
KR (1) KR20230022164A (https=)
AU (1) AU2021273460A1 (https=)
BR (1) BR112022022599A2 (https=)
CA (1) CA3177913A1 (https=)
IL (1) IL298008A (https=)
MX (1) MX2022014034A (https=)
WO (1) WO2021231208A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3240963A1 (en) * 2021-12-23 2023-06-29 Steven Laplante Drug combinations for inhibiting coronavirus replication
WO2023170187A1 (en) * 2022-03-09 2023-09-14 Technische Universität München INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途
CN118903154B (zh) * 2024-08-22 2025-11-11 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 化合物CDDO-Im用于预防或治疗口蹄疫的新用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
CA2107894C (en) 1991-04-10 2003-10-14 Kenneth F. Buechler Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
ES2401741T3 (es) 2007-05-08 2013-04-24 Abbott Laboratories Ensayo de péptido natriurético de tipo B humano que tiene una reducida reactividad cruzada con otras formas péptidicas
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
KR100905466B1 (ko) 2007-10-08 2009-07-02 한국과학기술원 차세대 셀룰라 통신시스템에서의 중계 통신방법
BRPI0907423A2 (pt) 2008-01-11 2020-10-27 Reata Pharmaceuticals, Inc. composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto
WO2009146218A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
SI2395979T1 (sl) 2009-02-13 2017-12-29 Reata Pharmaceuticals, Inc. Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
DK2558105T3 (da) * 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
EP4736949A2 (en) * 2013-08-23 2026-05-06 Reata Pharmaceuticals Holdings, LLC Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
CN110198718B (zh) * 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
US11427533B2 (en) 2017-07-13 2022-08-30 Pliva Hrvatska D.O.O. Crystalline polymorphs of bardoxolone methyl
WO2021202547A1 (en) * 2020-04-01 2021-10-07 Triterpenoid Therapeutics, Inc. Methods and compositions for treating and preventing viral infection
WO2021202245A1 (en) * 2020-04-02 2021-10-07 Egaceutical Corporation Viral treatment regimens

Also Published As

Publication number Publication date
KR20230022164A (ko) 2023-02-14
MX2022014034A (es) 2023-01-11
EP4146226A1 (en) 2023-03-15
CN115803059A (zh) 2023-03-14
IL298008A (en) 2023-01-01
AU2021273460A1 (en) 2022-12-08
US20230255982A1 (en) 2023-08-17
WO2021231208A1 (en) 2021-11-18
JP2023526567A (ja) 2023-06-21
CA3177913A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
MX2021014742A (es) Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
BR112023020600A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
BR112022016413A2 (pt) Método para o tratamento ou prevenção do coronavírus causado pelo vírus coronavírus da síndrome respiratória aguda grave 2, composto, e, uso de um composto
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112016013961A2 (pt) angiotensina ii sozinha ou em combinação para o tratamento da hipotensão
BR112022021640A2 (pt) Usos e formulações de canabinoides
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
BR112023003427A2 (pt) Terapia com antagonista de lag-3 para carcinoma hepatocelular
BR112022015800A2 (pt) Tratamento de colangite biliar primária com elafibranor
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
BR112022018948A2 (pt) Métodos de tratamento de lesão pulmonar com inibidores de cgrp
BR112022018235A2 (pt) Método de tratamento, método para tratar síndrome do desconforto respiratório agudo, método para inibir uma resposta de citocina em um paciente, método para tratar lesão renal aguda e método para tratar trombose
MX2024005399A (es) Combinaciones farmaceuticas para el tratamiento de hbv.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
ZA202300493B (en) Antiviral use of liraglutide and gefitinib
MX2015011347A (es) Tratamiento sistemico y topico combinado de tejidos con trastorno.
MX2022005448A (es) Método de tratamiento de queratodermia palmoplantar.
BR112023016958A2 (pt) Compostos para uso no tratamento de uma infecção por vírus envelopado